| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary targets of (S)-Pro-xylane are the biosynthetic pathways of glycosaminoglycans (GAGs) in the extracellular matrix. It stimulates the synthesis of GAGs in human fibroblasts. The compound also promotes the synthesis of collagen fibers and hyaluronic acid in the dermis. It serves as a catalytic substrate for recombinant carbonyl reductase R129E/D210F. These activities contribute to its effects on skin hydration and elasticity.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that (S)-Pro-xylane (0.3-3.0 mM; 96 h) stimulates the synthesis of GAGs in human fibroblasts. The compound promotes the synthesis of collagen fibers and hyaluronic acid in the dermis. As a catalytic substrate of recombinant carbonyl reductase R129E/D210F, it is involved in enzymatic reactions. These in vitro activities form the basis for its use in anti-aging cosmetic applications.
|
| ln Vivo |
In vivo activity of (S)-Pro-xylane has been demonstrated in skin care applications where it improves skin hydration and elasticity. The compound is eco-friendly and biodegradable. Its ability to promote collagen and hyaluronic acid synthesis contributes to its anti-aging effects in vivo. Clinical and cosmetic studies have validated its efficacy in improving skin appearance.
|
| Enzyme Assay |
Non-cellular assays for (S)-Pro-xylane typically involve enzymatic activity measurements using recombinant carbonyl reductase R129E/D210F. The compound serves as a substrate, and enzyme activity is monitored spectrophotometrically by measuring the formation of reaction products. These cell-free systems allow for the characterization of the compound's role as a substrate in enzymatic reactions. Analytical techniques such as HPLC and NMR are used for compound characterization.
|
| Cell Assay |
Cellular assays for (S)-Pro-xylane are conducted using human fibroblasts. Cells are treated with the compound at concentrations ranging from 0.3 to 3.0 mM for 96 hours. Glycosaminoglycan (GAG) synthesis is measured using biochemical assays such as Alcian Blue staining or ELISA. Collagen and hyaluronic acid production are quantified using specific antibodies or biochemical assays. These assays demonstrate the compound's ability to stimulate extracellular matrix production.
|
| Animal Protocol |
In vivo animal experiments for (S)-Pro-xylane have not been extensively reported in the literature, as the compound is primarily used in cosmetic applications rather than as a therapeutic agent. The compound is considered safe and biodegradable. Skin care studies typically involve human subjects rather than animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (S)-Pro-xylane have not been extensively characterized, as the compound is used in topical cosmetic applications rather than as a systemically administered therapeutic agent. Its molecular weight (192.21 g/mol) and C-glycoside structure suggest that it may have limited oral bioavailability. The compound is stable and biodegradable. Storage conditions and stability data are available from chemical suppliers.
|
| Toxicity/Toxicokinetics |
Toxicological data for (S)-Pro-xylane indicate that it is safe for use in cosmetic applications. The compound is eco-friendly and biodegradable. No significant toxicity has been reported for this compound. It is considered non-irritating and non-sensitizing at the concentrations used in cosmetic formulations. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
[1]. Cavezza A, et al. Synthesis of Pro-Xylane: a new biologically active C-glycoside in aqueous media. Bioorg Med Chem Lett. 2009 Feb 1;19(3):845-9.
|
| Additional Infomation |
Other information includes the compound's use as an anti-aging cosmetic ingredient. It promotes the synthesis of collagen fibers and hyaluronic acid in the dermis, improving skin hydration and elasticity. (S)-Pro-xylane is the S-enantiomer of Pro-xylane and is a bioactive C-glycoside that acts as a biosynthetic activator of glycosaminoglycans. It is eco-friendly and biodegradable. The compound is derived from xylose.
|
| Molecular Formula |
C8H16O5
|
|---|---|
| Molecular Weight |
192.209643363953
|
| Exact Mass |
192.099
|
| CAS # |
868156-46-1
|
| Related CAS # |
Pro-xylane;439685-79-7
|
| PubChem CID |
59696975
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@@H](C[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)O
|
| InChi Key |
KOGFZZYPPGQZFZ-BJNUKLAGSA-N
|
| InChi Code |
InChI=1S/C8H16O5/c1-4(9)2-6-8(12)7(11)5(10)3-13-6/h4-12H,2-3H2,1H3/t4-,5+,6-,7-,8-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5R)-2-[(2S)-2-hydroxypropyl]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (1300.66 mM)
H2O: 100 mg/mL (520.26 mM） |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (520.26 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2026 mL | 26.0132 mL | 52.0264 mL | |
| 5 mM | 1.0405 mL | 5.2026 mL | 10.4053 mL | |
| 10 mM | 0.5203 mL | 2.6013 mL | 5.2026 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
